CN112546136A - Theaflavin tablet for preventing dental caries and its production process - Google Patents
Theaflavin tablet for preventing dental caries and its production process Download PDFInfo
- Publication number
- CN112546136A CN112546136A CN202011514792.6A CN202011514792A CN112546136A CN 112546136 A CN112546136 A CN 112546136A CN 202011514792 A CN202011514792 A CN 202011514792A CN 112546136 A CN112546136 A CN 112546136A
- Authority
- CN
- China
- Prior art keywords
- theaflavin
- percent
- aloe
- tea
- dental caries
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a theaflavin film for preventing dental caries and a production process thereof, wherein the theaflavin film comprises a tea extract, the tea extract comprises theaflavin, tea polyphenol and tea polysaccharide, and the mass ratio of the theaflavin to the tea polyphenol to the tea polysaccharide is (3-5): 1-2: 0.5 to 1; the aloe extract comprises aloin, aloe-emodin and aloe-emodin, and the mass ratio of the aloin to the aloe-emodin is 1-2: 1-3: 1-2. The theaflavin film for preventing the decayed tooth of the invention contains theaflavin, tea polyphenol and tea polyphenol in a certain proportion, and the aloe extract is added simultaneously through compatibility and synergy, so that the obtained toothpaste has obvious bacteriostatic action, can greatly reduce cariogenic bacteria, has good taste, can be quickly dissolved and easily absorbed, and can quickly reach all parts of the oral cavity.
Description
Technical Field
The invention belongs to the technical field of caries prevention products, and particularly relates to a theaflavin film for preventing caries and a production process thereof.
Background
Dental caries, commonly known as decayed tooth and decayed tooth, is a bacterial disease and can cause secondary pulpitis and periapical periodontitis, and even alveolar bone and jaw inflammation. If the treatment is not carried out in time, the lesion continues to develop to form a cavity, and finally the dental crown is completely destroyed and disappears. Untreated caries cavities do not heal on their own and the end result of their development is tooth loss. The generation of the decayed tooth is closely related to the imbalance of the oral cavity symbiotic flora structure, and the maintenance of the oral cavity cleanness and sanitation and the regulation of the flora balance are the fundamental strategies for preventing the decayed tooth.
At present, products for preventing dental caries mainly comprise fluorine-containing preparations and gargle containing antibacterial drugs, but the fluorine-containing preparations can cause incomplete mouth washing or mistaken swallowing, so that excessive fluorine intake is easily caused, and potential health hazards exist; the gargle containing the antibacterial drug has obvious side effects such as broad-spectrum sterilization, drug resistance and the like, and can easily cause oral flora imbalance after long-term continuous use, thereby becoming a cause of various oral diseases.
The theaflavin is a product of oxidation polymerization of catechin components in the fermentation process of black tea, has a unique benzoaltophenone structure and more phenolic hydroxyl groups, and is superior to catechin and other polyphenol components in antibacterial performance. The theaflavin serving as a natural broad-spectrum bacteriostatic agent has potential application value in the intervention of various pathogenic bacteria related to human beings.
Related patents on applying theaflavin to the prevention of dental caries exist, but the single theaflavin has poor bacteriostatic effect on the prevention of dental caries, and a space for improvement exists; in addition, in the prior art, the anti-caries product formula containing theaflavin contacts the oral cavity by being prepared into toothpaste, so that various parts of the oral cavity cannot be reached quickly, and the effective concentration of the tea-yellow wine entering the oral cavity is low.
Disclosure of Invention
The invention aims to provide a theaflavin film for preventing dental caries, which contains theaflavin, tea polyphenol and tea polyphenol in a certain proportion, and the obtained toothpaste has obvious bacteriostatic action and can greatly reduce cariogenic bacteria by compatibility and cooperation.
The technical scheme adopted by the invention for solving the problems is as follows: the theaflavin film for preventing dental caries comprises a tea extract, wherein the tea extract comprises theaflavin, tea polyphenol and tea polysaccharide, and the mass ratio of the theaflavin to the tea polyphenol to the tea polysaccharide is (3-5): 1-2: 0.5 to 1.
Preferably, the theaflavin membrane for preventing dental caries further comprises an aloe extract, wherein the aloe extract comprises aloin, aloe-emodin and aloe-emodin, and the mass ratio of the aloin to the aloe-emodin is 1-2: 1-3: 1-2.
Preferably, the theaflavin tablet for preventing dental caries comprises the following components in percentage by weight:
9-12% of tea extract
1.5 to 3 percent of aloe extract
65-80% of film-forming agent
2 to 5 percent of humectant
2 to 5 percent of adhesive
2.3 to 4.6 percent of sweetening agent
1 to 2 percent of emulsifier
0.3 to 0.5 percent of thickening agent
0.2 to 0.4 percent of acidity regulator
More preferably, the theaflavin tablet for preventing dental caries comprises the following components in percentage by weight:
tea leaf extract 9.2%
Aloe extract 2%
76.68 percent of film forming agent
Humectant 3%
4 percent of adhesive
3.42 percent of sweetening agent
1 percent of emulsifier
0.4 percent of thickening agent
0.3 percent of acidity regulator
More preferably, the film forming agent is pullulan, the adhesive is starch, the emulsifier is monoglyceride, the thickener is carrageenan, and the acidity regulator is citric acid.
More preferably, the humectant is at least one of sorbitol, glycerol, polyethylene glycol and betaine, the sweetener is composed of solid sugar and liquid sugar, and the mass ratio of the solid sugar to the liquid sugar is 0.3-0.6: 2 to 4.
More preferably, the humectant is glycerin, the solid sugar is erythritol, and the liquid sugar is maltose syrup.
Another object of the present invention is to provide a process for producing a theaflavin tablet for prevention of dental caries, comprising the steps of:
(1) weighing the following components in proportion: tea extract, aloe extract, film forming agent, humectant, adhesive, sweetener, emulsifier, thickener, and acidity regulator.
(2) And (2) mixing the components in the step (1) to obtain a mixture, heating and stirring the mixture and water in proportion, and pulping by using a pulping machine to prepare slurry.
(3) And (3) filtering the slurry obtained in the step (2) by using a filter, and homogenizing by using a colloid mill to obtain an intermediate.
(4) Emulsifying the intermediate obtained in the step (3).
(5) And (4) filtering the emulsion obtained in the step (4) through vacuum defoaming, standing and preserving heat.
(6) Filtering the slurry after standing and heat preservation in the step (5), coating, and drying.
(7) And (4) sequentially rolling the film dried in the step (6), stably forming, slicing and forming to obtain the theaflavin film.
Preferably, the mass ratio of the mixture to the water in the step (2) is 1: 2-5, wherein the heating temperature is 70-80 ℃, and stirring is carried out for 1-2 hours; the mesh number of the filter in the step (3) is 300 meshes.
Preferably, the standing and heat-preserving time in the step (5) is 1.5-3 hours, and the standing and heat-preserving temperature is 55-75 ℃; in the step (6), the thickness of the coating film is 0.03-0.06 mm, the drying temperature is 60-70 ℃, and the drying time is 2-5 h.
Compared with the prior art, the invention has the advantages that:
(1) the theaflavin film for preventing decayed teeth of the invention adopts the sweetening agent consisting of solid sugar (erythritol) and liquid sugar (maltose syrup) according to a certain proportion, improves the taste and the human acceptance, can be quickly dissolved after entering the oral cavity, and can quickly reach all parts of the oral cavity to effectively inhibit various oral harmful bacteria.
(2) The theaflavin membrane for preventing the decayed teeth contains theaflavin, tea polyphenol and tea polyphenol in a certain proportion, the obtained theaflavin membrane has obvious bacteriostatic action through compatibility and cooperation, and meanwhile, a certain amount of aloe extracts (aloin, aloe-emodin and aloe-emodin) are added, so that the decayed tooth bacteria can be greatly reduced.
Drawings
FIG. 1 is a process flow diagram of the production process of a theaflavin tablet for prevention of dental caries in accordance with the present invention.
Detailed Description
The invention is described in further detail below with reference to the accompanying examples.
As shown in FIG. 1, the process flow chart of the production process of the theaflavin tablet for preventing dental caries according to the present invention.
Example 1
A theaflavin tablet for preventing dental caries comprises the following components by weight percent:
76.68 percent of pullulan polysaccharide
Tea leaf extract 9.2%
Aloe extract 2%
Starch 4%
3 percent of glycerin
Maltose syrup 3%
1 percent of monoglyceride
Erythritol 0.42%
0.4 percent of carrageenan
0.3 percent of citric acid
Wherein the tea extract is prepared from the following components in a mass ratio of 3: 1: 0.5 of a mixture of theaflavin, tea polyphenols, tea polysaccharides; the aloe extract is a mixture of aloin, aloe-emodin and aloe-emodin with the mass ratio of 1:1: 1.
A production process of theaflavin tablet for preventing dental caries comprises the following steps:
(1) weighing the following components in proportion: pullulan, tea extract, aloe extract, starch, glycerol, maltose syrup, monoglyceride, erythritol, carrageenan and citric acid.
(2) Mixing the components in the step (1) to obtain a mixture, mixing the mixture and water according to the mass ratio of 1:5, heating and stirring at the heating temperature of 80 ℃, stirring for 1h, and pulping by using a pulping machine to prepare slurry.
(3) And (3) filtering the slurry obtained in the step (2) by using a 300-mesh filter, and homogenizing by using a colloid mill to obtain an intermediate.
(4) Emulsifying the intermediate obtained in the step (3).
(5) And (4) filtering the emulsion obtained in the step (4) through vacuum defoaming, and standing and preserving heat for 2 hours at the temperature of 60 ℃.
(6) Filtering the slurry obtained in the step (5) after standing and heat preservation, coating the slurry to a thickness of 0.04mm, and drying the slurry at 70 ℃ for 3 h.
(7) And (4) sequentially rolling the film dried in the step (6), stably forming, slicing and forming to obtain the theaflavin film.
Example 2
A theaflavin tablet for preventing dental caries comprises the following components by weight percent:
76.68 percent of pullulan polysaccharide
Tea leaf extract 9.2%
Aloe extract 2%
Starch 4%
3 percent of glycerin
Maltose syrup 3%
1 percent of monoglyceride
Erythritol 0.42%
0.4 percent of carrageenan
0.3 percent of citric acid
Wherein the tea extract is prepared from the following components in percentage by mass: 2:1 of theaflavin, tea polyphenols, tea polysaccharides; the aloe extract is a mixture of aloin, aloe-emodin and aloe-emodin with the mass ratio of 2:3: 2.
A production process of theaflavin tablet for preventing dental caries comprises the following steps:
(1) weighing the following components in proportion: pullulan, tea extract, aloe extract, starch, glycerol, maltose syrup, monoglyceride, erythritol, carrageenan and citric acid.
(2) Mixing the components in the step (1) to obtain a mixture, mixing the mixture and water according to the mass ratio of 1:4, heating and stirring at the temperature of 70 ℃, stirring for 2 hours, and pulping by using a pulping machine to prepare slurry.
(3) And (3) filtering the slurry obtained in the step (2) by using a 300-mesh filter, and homogenizing by using a colloid mill to obtain an intermediate.
(4) Emulsifying the intermediate obtained in the step (3).
(5) And (4) filtering the emulsion obtained in the step (4) through vacuum defoaming, and standing and preserving heat for 2 hours at the temperature of 60 ℃.
(6) Filtering the slurry obtained in the step (5) after standing and heat preservation, coating the slurry to a thickness of 0.04mm, and drying the slurry at 70 ℃ for 3 h.
(7) And (4) sequentially rolling the film dried in the step (6), stably forming, slicing and forming to obtain the theaflavin film.
Example 3
A theaflavin tablet for preventing dental caries comprises the following components by weight percent:
pullulan polysaccharide 75%
Tea extract 10.28%
Aloe extract 1.8%
Starch 4%
4 percent of glycerin
Maltose syrup 3%
1 percent of monoglyceride
Erythritol 0.42%
0.3 percent of carrageenan
0.2 percent of citric acid
Wherein the tea extract is prepared from the following components in a mass ratio of 3: 1: 0.5 of a mixture of theaflavin, tea polyphenols, tea polysaccharides; the aloe extract is a mixture of aloin, aloe-emodin and aloe-emodin with the mass ratio of 1:1: 1.
A production process of theaflavin tablet for preventing dental caries comprises the following steps:
(1) weighing the following components in proportion: pullulan, tea extract, aloe extract, starch, glycerol, maltose syrup, monoglyceride, erythritol, carrageenan and citric acid.
(2) Mixing the components in the step (1) to obtain a mixture, mixing the mixture and water according to the mass ratio of 1:5, heating and stirring at the heating temperature of 80 ℃, stirring for 1h, and pulping by using a pulping machine to prepare slurry.
(3) And (3) filtering the slurry obtained in the step (2) by using a 300-mesh filter, and homogenizing by using a colloid mill to obtain an intermediate.
(4) Emulsifying the intermediate obtained in the step (3).
(5) And (4) filtering the emulsion obtained in the step (4) through vacuum defoaming, and standing and preserving heat for 2 hours at the temperature of 60 ℃.
(6) Filtering the slurry obtained in the step (5) after standing and heat preservation, coating the slurry to a thickness of 0.04mm, and drying the slurry at 70 ℃ for 3 h.
(7) And (4) sequentially rolling the film dried in the step (6), stably forming, slicing and forming to obtain the theaflavin film.
Comparative example 1
The only difference from example 1 is: theaflavins are not included.
Comparative example 2
The only difference from example 1 is: tea polyphenols are not included.
Comparative example 3
The only difference from example 1 is: tea polysaccharides are not included.
Comparative example 4
The only difference from example 1 is: aloe vera extract is not included.
Comparative example 5
The only difference from example 1 is: the mass ratio of theaflavin, tea polyphenol and tea polysaccharide is 3: 5: 2.
examples 1-3 were carried out in comparison with comparative examples 1-5, with the following specific test conditions and test results:
(1) experiment grouping
24 mice with age of 23 days are selected and randomly divided into a trial group and a distilled water group, each group comprises 12 mice, each of which is half male and female, and ampicillin sodium (0.5 mu g/mL) is given to the mice for bacteriostasis in the age period of 23-25 days.
(2) Inoculation with cariogenic bacteria
The 25-day old mice are fed with cariogenic feed 2000# and 5% sucrose water, and during the period of 26-30 days old mice, the oral cavity of each rat is inoculated with streptococcus mutans (107CFU/mL) for 5 consecutive days, and each rat is inoculated with 1 mL.
(3) Experimental methods
Treating rats with membrane and distilled water respectively from 31 days, taking animals in supine position, cutting one membrane, placing on teeth and oral cavity of rat, dissolving the membrane completely, maintaining the medicinal liquid in tooth surface and oral cavity of rat for 15s, treating for 1 time every day, stopping eating within 30 min, and continuously treating for 60 days. When the mouse is 89 days old, taking saliva of the rat for culturing, and counting streptococcus mutans colonies after 48 hours; then taking a jaw bone specimen, and evaluating the cariostatic effect of the diaphragm according to a Keyes grading method.
(4) Results of the experiment
TABLE 1 Streptococcus mutans colony count results
| Group of | Colony count CFU/ml |
| Example 1 | 2.5×103 |
| Example 2 | 2.0×103 |
| Example 3 | 2.2×103 |
| Comparative example 1 | 7.1×105 |
| Comparative example 2 | 1.2×105 |
| Comparative example 3 | 5.6×104 |
| Comparative example 4 | 4.9×104 |
| Comparative example 5 | 3.2×104 |
| Control group | 1.6×106 |
TABLE 2 caries lesion status of the experimental groups
| Group of | Caries lesion of grade E | DSGrade caries lesions | DMGrade caries lesions | DXGrade caries lesions |
| Example 1 | 32.45±1.571 | 28.419±2.723 | 9.324±2.538 | 0.128±0.181 |
| Example 2 | 33.23±1.517 | 28.815±2.737 | 9.891±2.683 | 0.141±0.191 |
| Example 3 | 32.99±1.598 | 29.027±2.934 | 9.789±2.780 | 0.130±0.200 |
| Comparative example 1 | 36.89±1.678 | 33.449±2.765 | 20.377±2.234 | 8.122±0.112 |
| Comparative example 2 | 35.45±1.234 | 32.998±2.654 | 18.893±2.333 | 6.183±0.177 |
| Comparative example 3 | 33.77±1.340 | 32.409±2.261 | 12.234±2.451 | 2.782±0.166 |
| Comparative example 4 | 33.45±1.560 | 32.101±2.721 | 11.999±2.531 | 2.456±0.171 |
| Comparative example 5 | 33.01±1.521 | 31.419±2.629 | 10.345±2.445 | 1.887±0.145 |
| Control group | 38.17±1.615 | 35.780±2.185 | 24.83±3.168 | 11.41±2.544 |
Note: caries progression was classified into 4 levels of enamel layer (level E), superficial dentin layer (Ds), middle dentin layer (Dm), and deep dentin layer (Dx).
As can be seen from tables 1 and 2, the difference between the two groups was very significant, and the scoring results showed that the degree and amount of caries were significantly less in the examples than in the control group, and the pellicle was effective in inhibiting the onset and progression of caries.
In addition to the above embodiments, the present invention also includes other embodiments, and any technical solutions formed by equivalent transformation or equivalent replacement should fall within the scope of the claims of the present invention.
Claims (10)
1. A theaflavin tablet for preventing dental caries, comprising: the tea extract comprises theaflavin, tea polyphenol and tea polysaccharide, wherein the mass ratio of the theaflavin to the tea polyphenol to the tea polysaccharide is (3-5): 1-2: 0.5 to 1.
2. The theaflavin tablet for prevention of dental caries according to claim 1 wherein: the theaflavin membrane for preventing the decayed teeth also comprises an aloe extract, wherein the aloe extract comprises aloin, aloe-emodin and aloe-chrysophanol, and the mass ratio of the aloin to the aloe-emodin to the aloe-chrysophanol is 1-2: 1-3: 1-2.
3. The theaflavin tablet for prevention of dental caries according to claim 1 wherein: the paint comprises the following components in percentage by weight:
9-12% of tea extract
1.5 to 3 percent of aloe extract
65-80% of film-forming agent
2 to 5 percent of humectant
2 to 5 percent of adhesive
2.3 to 4.6 percent of sweetening agent
1 to 2 percent of emulsifier
0.3 to 0.5 percent of thickening agent
0.2-0.4% of acidity regulator.
4. The theaflavin tablet for prevention of dental caries according to claim 3 wherein: the paint comprises the following components in percentage by weight:
tea leaf extract 9.2%
Aloe extract 2%
76.68 percent of film forming agent
Humectant 3%
4 percent of adhesive
3.42 percent of sweetening agent
1 percent of emulsifier
0.4 percent of thickening agent
0.3 percent of acidity regulator.
5. The theaflavin tablet for prevention of dental caries according to claim 3 wherein: the film forming agent is pullulan polysaccharide, the adhesive is starch, the emulsifier is monoglyceride, the thickening agent is carrageenan, and the acidity regulator is citric acid.
6. The theaflavin tablet for prevention of dental caries according to claim 3 wherein: the humectant is at least one of sorbitol, glycerol, polyethylene glycol and betaine, the sweetener is composed of solid sugar and liquid sugar, and the mass ratio of the solid sugar to the liquid sugar is (0.3-0.6): 2 to 4.
7. The theaflavin tablet for prevention of dental caries according to claim 6 wherein: the humectant is glycerin, the solid sugar is erythritol, and the liquid sugar is maltose syrup.
8. A production process of theaflavin film for preventing dental caries is characterized in that: the method comprises the following steps:
(1) weighing the following components in proportion: tea extract, aloe extract, film forming agent, humectant, adhesive, sweetener, emulsifier, thickener, and acidity regulator;
(2) mixing the components in the step (1) to obtain a mixture, heating and stirring the mixture and water in proportion, and pulping by using a pulping machine to prepare a slurry;
(3) filtering the slurry obtained in the step (2) by using a filter, and homogenizing by using a colloid mill to obtain an intermediate;
(4) emulsifying the intermediate obtained in the step (3);
(5) filtering the emulsion obtained in the step (4) in vacuum defoamation, standing and preserving heat;
(6) filtering the slurry obtained in the step (5) after standing and heat preservation, coating, and drying;
(7) and (4) sequentially rolling the film dried in the step (6), stably forming, slicing and forming to obtain the theaflavin film.
9. The process for producing a theaflavin tablet for prevention of dental caries according to claim 8, characterized by: the mass ratio of the mixture to water in the step (2) is 1: 2-5, wherein the heating temperature is 70-80 ℃, and stirring is carried out for 1-2 hours; the mesh number of the filter in the step (3) is 300 meshes.
10. The process for producing a theaflavin tablet for prevention of dental caries according to claim 8, characterized by: standing and insulating time in the step (5) is 1.5-3 h, and standing and insulating temperature is 55-75 ℃; in the step (6), the thickness of the coating film is 0.03-0.06 mm, the drying temperature is 60-70 ℃, and the drying time is 2-5 h.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011514792.6A CN112546136A (en) | 2020-12-21 | 2020-12-21 | Theaflavin tablet for preventing dental caries and its production process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011514792.6A CN112546136A (en) | 2020-12-21 | 2020-12-21 | Theaflavin tablet for preventing dental caries and its production process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112546136A true CN112546136A (en) | 2021-03-26 |
Family
ID=75030999
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011514792.6A Pending CN112546136A (en) | 2020-12-21 | 2020-12-21 | Theaflavin tablet for preventing dental caries and its production process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112546136A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101235025A (en) * | 2008-02-29 | 2008-08-06 | 天津科技大学 | Method for preparing theaflavin |
| CN101755954A (en) * | 2009-09-29 | 2010-06-30 | 刘宝 | Method for preparing floatable solid-state instant pu-erh tea cream |
| CN107865966A (en) * | 2016-09-23 | 2018-04-03 | 刘力 | The compound amino glycoside pharmaceutical composition being locally administered |
| CN110250310A (en) * | 2019-06-24 | 2019-09-20 | 仙乐健康科技股份有限公司 | A kind of high-moisture gel candy and preparation method thereof |
| CN110680788A (en) * | 2019-11-20 | 2020-01-14 | 茗汲(浙江)生物科技有限公司 | Toothpaste containing tea extract and preparation process |
| US20200289391A1 (en) * | 2019-03-11 | 2020-09-17 | Dosebiome Inc. | Compositions and methods for inhibiting growth of caries-, gingivitis- and halitosis-causing bacteria |
-
2020
- 2020-12-21 CN CN202011514792.6A patent/CN112546136A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101235025A (en) * | 2008-02-29 | 2008-08-06 | 天津科技大学 | Method for preparing theaflavin |
| CN101755954A (en) * | 2009-09-29 | 2010-06-30 | 刘宝 | Method for preparing floatable solid-state instant pu-erh tea cream |
| CN107865966A (en) * | 2016-09-23 | 2018-04-03 | 刘力 | The compound amino glycoside pharmaceutical composition being locally administered |
| US20200289391A1 (en) * | 2019-03-11 | 2020-09-17 | Dosebiome Inc. | Compositions and methods for inhibiting growth of caries-, gingivitis- and halitosis-causing bacteria |
| CN110250310A (en) * | 2019-06-24 | 2019-09-20 | 仙乐健康科技股份有限公司 | A kind of high-moisture gel candy and preparation method thereof |
| CN110680788A (en) * | 2019-11-20 | 2020-01-14 | 茗汲(浙江)生物科技有限公司 | Toothpaste containing tea extract and preparation process |
Non-Patent Citations (5)
| Title |
|---|
| MAO-JUNG LEE,等: "Delivery of Tea Polyphenols to the Oral Cavity by Green Tea Leaves and Black Tea Extract", 《CANCER EPIDEMIOLOGY, BIOMARKERS & PREVENTION》 * |
| 孔俊豪等: "2018年中国茶叶深加工科技创新进展", 《中国茶叶加工》 * |
| 张珍珍: "茶防龋研究进展", 《人人健康》 * |
| 范士忠: "药食皆优的芦荟", 《东方药膳》 * |
| 魏平: "《临床药学新进展》", 31 May 2015, 西安交通大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101467316B1 (en) | Oral cleansing composition fermented taraxacum extract-containing complex herbal extract | |
| CN107595750B (en) | Active anti-inflammation toothpaste | |
| CN107468553B (en) | Dental caries prevention toothpaste | |
| CN107106477B (en) | Oral care compositions and methods of use | |
| CN107811890A (en) | A kind of oral cavity caring toothpaste composition | |
| CN107049828A (en) | A kind of anti-caries toothpaste and preparation method thereof | |
| CN107375168A (en) | A kind of anti-caries toothpaste of American-cockroach-extract-containing | |
| US20150359835A1 (en) | Composition of a medical device or cosmetic product based on grapefruit seed extract, lady's mantle leaf extract, stevia extract, and curcumin | |
| CN112618451A (en) | Composition containing natural antibacterial ingredients and application | |
| CN111956682A (en) | A butyrum-boron cream for treating stomatitis and gingivitis, and its preparation method and application | |
| CN112546136A (en) | Theaflavin tablet for preventing dental caries and its production process | |
| CN114795997B (en) | NMN-containing amino acid toothpaste and preparation method thereof | |
| CN107242983B (en) | Mouth wash containing folium artemisiae argyi flavone and preparation method thereof | |
| CN106420938B (en) | A kind of Chinese medicine composition and preparation method thereof for treating oral inflammation and pharyngitis | |
| CN113197830B (en) | Toothpaste and preparation method thereof | |
| CN111617021B (en) | Toothpaste for resisting oral helicobacter pylori | |
| CN114053331B (en) | Oral antibacterial composition, oral antibacterial liquid, application and preparation method | |
| KR20190057727A (en) | Composition for improving bronchial health improved palatability | |
| CN114159500A (en) | Hyaluronic acid essential oil composition for nourishing and repairing oral cavity and application thereof | |
| CN108635283B (en) | Antibacterial composition, antibacterial toothpaste and preparation method thereof | |
| CN107362112B (en) | Gum-protecting and healing toothpaste | |
| KR20180054533A (en) | Raspberry leaf fermentation, nasal cavity, oral, throat, skin, cleansing(gargle) beverages, The compositions of the manufacturing process | |
| KR20150040818A (en) | Oral Hygiene functional composition and a method of manufacturing | |
| CN112336678B (en) | Toothpaste capable of freshening breath | |
| CN109044898A (en) | A kind of hemostasis oral cavity nursing agent of brilliant white fresh breath type |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210326 |
|
| RJ01 | Rejection of invention patent application after publication |